Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer.

ABSTRACT:

SUBMITTER: Devaux A 

PROVIDER: S-EPMC12661675 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature